MERZ-THERAPEUTICS
2.4.2024 08:29:33 CEST | Business Wire | Press release
Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered into an Asset Purchase Agreement to acquire two commercial medicines from NASDAQ-listed Acorda Therapeutics. Closing of the transaction would significantly contribute to the accelerated growth strategy of Merz Therapeutics.
“Our specialty-neurology focused business Merz Therapeutics has developed very well in recent years. This investment would add significantly to Merz Therapeutics growth strategy and expand our portfolio in the field of movement disorders and neurodegeneration. In addition, it will strengthen the market position in North America” says Jörg Bergler, COO of the Merz Group. "We are excited about the development of Merz Therapeutics and are convinced that the purchase of the two drugs - one for the treatment of OFF phases of Parkinson's disease (PD) and one for the treatment of gait disorders in multiple sclerosis - would be of great value to both physicians and patients."
The acquisition will be processed through a court structured 363 sale process under the U.S. Bankruptcy Code, where Merz Therapeutics will provide the opening in the auction. The purchase price offered by Merz is USD 185 million. The completion of the sale process is expected in June 2024, with any sale subject to court approval.
For the family-owned Merz Group, headquartered in Frankfurt, this investment would be the third transaction in the US in just over 10 years and the second time with a NASDAQ-listed company. "Merz has grown strongly in recent years - organically, but also through strategic acquisitions, especially in North America. We have solid experience in both the acquisition and integration of US companies or products. As a German-based but global company, we are very interested in innovative acquisitions, on a global scale," concludes Jörg Bergler.
Stefan König, CEO of Merz Therapeutics, adds, “As a patient-focused, innovative company we recognize the responsibility of providing continued patient care and support for Acorda’s well-established and innovative therapies and see this as an optimal potential portfolio expansion that underscores our ambition in key therapeutic areas.”
About Merz Group
Merz Group is a global, diversified company in the healthcare sector based in Frankfurt, Germany. Family-owned for over 116 years, the company is distinguished by its commitment to innovation, long-term perspective, and focus on profitable growth. Merz Group includes the businesses Merz Aesthetics, Merz Therapeutics, Merz Consumer Care, Merz Real Estate, and Merz Financial Investments. The company employs 4,337 people (as of the 22/23 financial year) in 28 countries worldwide. To learn more, please visit www.merz.com.
About Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group. Please visit www.merztherapeutics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401849394/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
Global Stars Ahn Hyo-seop and Khalid Release New Cross-Market Single “Something Special” via FANDOM Today22.5.2026 06:00:00 CEST | Press release
Produced by Woo “RAINSTONE” Rhee and Grammy Award-Winning Producer Troy “R8DIO” JohnsonStream the Single HERE For approved imagery, please download HERE Today marks the official release of “Something Special,” the highly anticipated cross-market collaboration from international star Ahn Hyo-seop and multi-platinum recording artist Khalid, available now via FANDOM on all major streaming platforms. Stream the single HERE. Musicow will also release an official music video in June, highlighting the unique chemistry between Ahn Hyo-seop and Khalid while bringing the song’s cross-cultural collaboration to life on screen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522928365/en/ Ahn Hyo-seop, globally recognized for his breakout role as “Jinu,” the leader of demon boy band Saja Boys in Netflix’s animated phenomenon KPop Demon Hunters, joins forces with Grammy-nominated artist Khalid for a genre-blending release that bridges t
Lenovo Group: Q4 and Full Year Financial Results 2025/2622.5.2026 01:47:00 CEST | Press release
Lenovo delivers exceptional fourth quarter results – maintaining growth and concluding strongest year in the Group’s history Lenovo GroupLimited (HKSE: 992) (ADR: LNVGY), together with its subsidiaries (‘the Group’), today reported fourth quarter and full year results for fiscal year 2025/26, marking an exceptional Q4 and the strongest year in the Group’s history. During the quarter, overall Group revenue reached an all-time fourth quarter high of US$21.6 billion, up 27% year-on-year, marking the highest year-on-year growth rate in five years, with adjusted net income[1]doubling year-on-year to US$559 million. AI-related revenue[2] stood out as a leading growth engine, growing 84% year-on-year to account for 38% of total Group revenue in Q4. For the full year, the Group delivered record revenue of US$83.1 billion, with adjusted net income growing 42% year-on-year to US$2 billion. All business groups achieved solid double-digit year-on-year revenue growth, with a notable record full-yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom